Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Neuroprotective effect of sevoflurane in general anaesthesia
Journal Information
Vol. 148. Issue 4.
Pages 158-160 (February 2017)
Download PDF
More article options
Vol. 148. Issue 4.
Pages 158-160 (February 2017)
Brief report
DOI: 10.1016/j.medcle.2016.10.050
Neuroprotective effect of sevoflurane in general anaesthesia
Efecto neuroprotector del sevoflurano en anestesia general
Victoria Ramos Ramosa, Pablo Mesa Suárezb, José Diego Santotoribioc,d,
Corresponding author

Corresponding author.
, María Ángela González Garcíae, Antonio Muñoz Hoyosf
a Unidad de Gestión Clínica de Pediatría, Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain
b Unidad de Gestión Clínica de Anestesiología, Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain
c Unidad de Gestión Clínica de Laboratorio, Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain
d Departamento de Biomedicina, Biotecnología y Salud Pública, Universidad de Cádiz, Cádiz, Spain
e Unidad de Gestión Clínica de Análisis Clínicos, Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain
f Departamento de Pediatría, Universidad de Granada, Granada, Spain
Article information
Full Text
Download PDF
Tables (1)
Table 1. Descriptive statistics of serum S100B protein concentration in the baseline sample and postexposure sample, and the difference between the two.
Introduction and objective

The aim of this study was to evaluate the brain damage caused by inhaled sevoflurane, by determining the concentration of serum S100B protein before and after the exposure to this drug as the only anaesthetic agent.

Patients and method

Paediatric patients undergoing general anaesthesia for the conduct of a nuclear magnetic resonance were included in the study. A venous blood sample was taken from each patient before (basal sample) and after (post-exposure sample) administering the general anaesthesia. The concentration of serum S100B protein was determined in the basal (S100Bb) and post-exposure sample (S100Bp).


A total of 72 patients were included in the study, with a mean patient age of 2–13 years (median=6), 28 males and 44 females. S100Bp values (median=66.5ng/L) were significantly lower (p=.0059) than those of S100Bb (median=84.0ng/L). The median of the difference between S100Bp and S100Bb was −11.0ng/L.


Inhaled sevoflurane at low doses causes a decrease of serum S100B protein levels, hence, this drug could have a neuroprotective effect in the central nervous system.

S100B protein
General anaesthesia
Brain damage
Introducción y objetivo

El objetivo fue evaluar el daño cerebral producido por el sevoflurano inhalado mediante la determinación de la proteína S100B sérica antes y después de una exposición a este fármaco como único agente anestésico.

Pacientes y método

Se incluyeron pacientes pediátricos sometidos a resonancia magnética nuclear bajo anestesia general con sevoflurano inhalado a dosis baja. A todos los pacientes se les extrajo una muestra de sangre venosa, antes (muestra basal) y después de la anestesia general (muestra postexposición). Se determinó la concentración de la proteína S100B sérica en la muestra basal (S100Bb) y en la muestra postexposición (S100Bp).


Se incluyeron 72 pacientes entre 2 y 13 años (mediana=6), 28 niños y 44 niñas. Los valores de S100Bp (mediana=66,5ng/l) fueron significativamente inferiores (p=0,0059) a los de S100Bb (mediana=84,0ng/l). La mediana de las diferencias entre S100Bp y S100Bb resultó −11,0ng/l.


El sevoflurano inhalado a dosis bajas produce un descenso de la proteína S100B sérica, por lo que este fármaco podría tener un efecto neuroprotector a nivel del sistema nervioso central.

Palabras clave:
Proteína S100B
Anestesia general
Daño cerebral


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos